TW202237641A - 用於增加家畜體內治療劑半衰期之組合物及使用方法 - Google Patents

用於增加家畜體內治療劑半衰期之組合物及使用方法 Download PDF

Info

Publication number
TW202237641A
TW202237641A TW110145549A TW110145549A TW202237641A TW 202237641 A TW202237641 A TW 202237641A TW 110145549 A TW110145549 A TW 110145549A TW 110145549 A TW110145549 A TW 110145549A TW 202237641 A TW202237641 A TW 202237641A
Authority
TW
Taiwan
Prior art keywords
amino acid
livestock
wild
group
acid substitution
Prior art date
Application number
TW110145549A
Other languages
English (en)
Chinese (zh)
Inventor
威廉 布隆迪克
優爾根 霍恩
Original Assignee
美商英維特克斯股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商英維特克斯股份有限公司 filed Critical 美商英維特克斯股份有限公司
Publication of TW202237641A publication Critical patent/TW202237641A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW110145549A 2020-12-07 2021-12-06 用於增加家畜體內治療劑半衰期之組合物及使用方法 TW202237641A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063122365P 2020-12-07 2020-12-07
US63/122,365 2020-12-07

Publications (1)

Publication Number Publication Date
TW202237641A true TW202237641A (zh) 2022-10-01

Family

ID=81848817

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110145549A TW202237641A (zh) 2020-12-07 2021-12-06 用於增加家畜體內治療劑半衰期之組合物及使用方法

Country Status (10)

Country Link
US (1) US20220177549A1 (de)
EP (1) EP4255933A1 (de)
JP (1) JP2023552456A (de)
KR (1) KR20230128283A (de)
CN (1) CN117043190A (de)
AU (1) AU2021397693A1 (de)
CA (1) CA3201120A1 (de)
MX (1) MX2023006639A (de)
TW (1) TW202237641A (de)
WO (1) WO2022125355A1 (de)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005123780A2 (en) * 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
US20060074225A1 (en) * 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
US20150050269A1 (en) * 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
NZ711451A (en) * 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
SG11201810466PA (en) * 2016-05-23 2018-12-28 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
WO2018151841A1 (en) * 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
JP7264381B2 (ja) * 2017-04-07 2023-04-25 国民大学校産学協力団 血中半減期の向上のための抗体Ｆｃ変異体
MX2021008144A (es) * 2019-01-03 2021-10-13 Invetx Inc Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso.
BR112022027028A2 (pt) * 2020-07-10 2023-03-07 Invetx Inc Composições para aumentar a meia-vida de um agente terapêutico em felinos e métodos de uso

Also Published As

Publication number Publication date
MX2023006639A (es) 2023-08-16
EP4255933A1 (de) 2023-10-11
CA3201120A1 (en) 2022-06-16
CN117043190A (zh) 2023-11-10
KR20230128283A (ko) 2023-09-04
JP2023552456A (ja) 2023-12-15
US20220177549A1 (en) 2022-06-09
AU2021397693A1 (en) 2023-07-13
WO2022125355A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
US11548949B2 (en) Compositions for increasing half-life of a therapeutic agent in canines and methods of use
US20200181258A1 (en) Modified antibody constant region
US11739135B2 (en) Compositions for increasing half-life of a therapeutic agent in felines and methods of use
US11434276B2 (en) Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use
US20230348577A1 (en) Modified fc regions
US20220177549A1 (en) Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of use